Journal of Biological Response Modifiers
Overview
Journal of Biological Response Modifiers is a scientific journal, published since 1982 in English. The journal's country of origin is United States and its primary focus areas are oncology, pharmacology and allergy & immunology.
Details
Details
Abbr.
J Biol Response Mod
Start
1982
End
1990
Frequency
Bimonthly
p-ISSN
0732-6580
Country
United States
Language
English
Specialties
Oncology
Pharmacology
Allergy & Immunology
Pharmacology
Allergy & Immunology
Recent Articles
1.
Von Hoff D, Fleming T, Macdonald J, Goodman P, Van Damme J, Brown T, et al.
J Biol Response Mod
. 1990 Dec;
9(6):584-7.
PMID: 2127424
Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant gamma-interferon. No responses were noted. Major...
2.
WHITEHEAD R, Fleming T, Macdonald J, Goodman P, Neefe J, Braun T, et al.
J Biol Response Mod
. 1990 Dec;
9(6):588-91.
PMID: 2074444
Tumor necrosis factor (TNF) induces hemorrhagic necrosis in the Meth A mouse tumor model and has shown cytostatic and cytotoxic antitumor effects against a wide range of human tumors both...
3.
Okutomi T, Inagawa H, Nishizawa T, Oshima H, Soma G, Mizuno D
J Biol Response Mod
. 1990 Dec;
9(6):564-9.
PMID: 2074443
Orally administered muramyl dipeptide (MDP) was found to prime induction of endogenous tumor necrosis factor (TNF) in mice. This priming effect was observed after oral administration of MDP of more...
4.
Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo
Murray J, Zukiwski A, Mujoo K, Rosenblum M
J Biol Response Mod
. 1990 Dec;
9(6):556-63.
PMID: 2074442
To determine whether recombinant human alpha-interferon (rIFN alpha A) could enhance tumor uptake of an antimelanoma monoclonal antibody (Mab) 96.5 in vivo, groups of nude mice bearing P97 antigen-positive human...
5.
Hercend T, Farace F, Baume D, Charpentier F, Droz J, Triebel F, et al.
J Biol Response Mod
. 1990 Dec;
9(6):546-55.
PMID: 2074441
Clinical immunotherapy trials have been performed recently where ex vivo interleukin-2 (IL-2)-activated peripheral blood mononuclear cells (i.e., the "LAK" cells) have been transfused in addition to IL-2 infusions. In such...
6.
Bukowski R, Murthy S, Sergi J, Budd G, McKeever S, Medendorp S, et al.
J Biol Response Mod
. 1990 Dec;
9(6):538-45.
PMID: 2074440
A phase I trial of high-dose continuous infusion rIL-2 over 5 days and i.m. recombinant human interferon-alpha (rHuIFN-alpha 2a) three times weekly in 23 patients with advanced malignancy has been...
7.
Sznol M, Mier J, Sparano J, Gaynor E, Weiss G, Margolin K, et al.
J Biol Response Mod
. 1990 Dec;
9(6):529-37.
PMID: 2074439
Our group and others have conducted phase II trials of high-dose interleukin-2 (IL-2) or IL-2 with the adoptive transfer of in vitro activated lymphocytes in patients with advanced malignancies. Although...
8.
Ullberg M, Tewodros W, Kronvall G
J Biol Response Mod
. 1990 Dec;
9(6):592-6.
PMID: 1963635
The biological response modifier OK-432, constituting cell wall fragments from a group A Streptococcus strain and used in anticancer therapy trials, was tested for its ability to interact with different...
9.
Mizushima Y, Morikage T, Kuwahara T, Yano S
J Biol Response Mod
. 1990 Dec;
9(6):576-83.
PMID: 1705961
The in vivo effects of the subcutaneous administration of the granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced hematopoietic injury were evaluated in BALB/c mice. Mice treated with chemotherapeutic drugs were injected...
10.
Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity
Richman C, Slapak C, Toh B
J Biol Response Mod
. 1990 Dec;
9(6):570-5.
PMID: 1705960
Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous...